HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BASF & vitamin C

This article was originally published in The Tan Sheet

Executive Summary

Company to shut down crystalline vitamin C line at Wilmington, N.C. facility by July 2002 but will continue to run vitamin C granulating, packaging operations at the site, ingredient supplier says Nov. 15. Move is aimed at strengthening BASF's market position by concentrating vitamin C manufacturing efforts "on areas that deliver better cost competitiveness and economies of scale," company says. BASF acquired the Wilmington site in January through its purchase of Takeda Chemical Industries' bulk vitamin business (1"The Tan Sheet" Aug. 7, 2000, p. 9)...

You may also be interested in...



BASF Global Vitamin Presence Strengthened With Takeda Combination

BASF's agreement to combine its bulk vitamins business with that of Takeda Chemical Industries considerably strengthens the chemical giant's position in the global vitamins market.

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel